Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
DiaSorin S.p.A., headquartered in Italy, is a prominent player in the pharmaceutical preparation manufacturing industry, specialising in the development and production of diagnostic solutions. Founded in 1968, the company has established a strong global presence, with significant operations across Europe, North America, and Asia.
DiaSorin is renowned for its innovative immunodiagnostic and molecular diagnostic products, which are designed to enhance patient care through accurate and timely testing. The company’s unique offerings include a wide range of assays for infectious diseases, oncology, and endocrinology, setting it apart in a competitive market.
With a commitment to research and development, DiaSorin has achieved notable milestones, including strategic acquisitions that have expanded its product portfolio and market reach. As a leader in the diagnostics field, DiaSorin continues to drive advancements that improve healthcare outcomes worldwide.
+24 vs industry average
Diasorin’s score of 66 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
DiaSorin, a Pharmaceutical Preparation Manufacturing company headquartered in IT, reported estimated total carbon emissions of approximately 113.8 million kg CO2e in 2025. This figure comprises about 4.2 million kg CO2e from Scope 1 emissions, 12.8 million kg CO2e from Scope 2 (market-based) emissions, and 96.8 million kg CO2e from Scope 3 emissions. Key contributors to Scope 3 emissions in 2025 included purchased goods and services (45.1 million kg CO2e), use of sold products (21.7 million kg CO2e), and business travel (17.2 million kg CO2e).
Looking back, DiaSorin's estimated total emissions were approximately 152.3 million kg CO2e in 2024, with around 3.5 million kg CO2e from Scope 1, 12.1 million kg CO2e from Scope 2 (market-based), and 136.7 million kg CO2e from Scope 3. In 2023, DiaSorin disclosed Scope 1 emissions of 3.9 million kg CO2e and Scope 2 emissions of 15.0 million kg CO2e. For 2022, Scope 1 emissions were 4.6 million kg CO2e and Scope 2 emissions were 15.3 million kg CO2e.
DiaSorin Ltd has committed to achieving Net Zero emissions by 2050 across all scopes. Furthermore, a near-term absolute reduction target projects that carbon emissions will decrease by 18.52% to 305,010 kg CO2e by 2028, based on a 2023 baseline.
All emissions data for DiaSorin is self-reported by DiaSorin S.p.A. and is not cascaded from a parent organization.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more